Casale, JF; Hays, PA. Ethylphenidate: An analytical profile. Microgram J., 1 Jan 2011, 8 (2), 58–61. 906 kB. MS,NMR,IR
Klare, H; Neudörfl, JM; Brandt, SD; Mischler, E; Meier-Giebing, S; Deluweit, K; Westphal, F; Laussmann, T. Analysis of six “neuro-enhancing” phenidate analogs. Drug Test. Anal., 1 Mar 2017, 9 (3), 423-435. 1.4 MB. https://doi.org/10.1002/dta.2161
Markowitz, JS; Zhu, H; Patrick, KS. Isopropylphenidate: An Ester Homolog of Methylphenidate with Sustained and Selective Dopaminergic Activity and Reduced Drug Interaction Liability. J. Child Adol. Psychop., 18 Dec 2013, 23 (10), 648–654. 328 kB. https://doi.org/10.1089/cap.2013.0074
Luethi, D; Kaeser, PJ; Brandt, SD; Krähenbühl, S; Hoener, MC; Liechti, ME. Pharmacological profile of methylphenidate-based designer drugs. Neuropharmacology, 15 May 2018, 134 (A), 133-140. 987 kB. https://doi.org/10.1016/j.neuropharm.2017.08.020
EMCDDA. New drugs in Europe, 2011, European Monitoring Centre for Drugs and Drug Addiction, Lisbon, 1 Apr 2012. 401 kB.
Jones, LE; Stewart, A; Peters, KL; McNaul, M; Speers, SJ; Fletcher, NC; Bell, SEJ. Infrared and Raman screening of seized novel psychoactive substances: a large scale study of >200 samples. Analyst, 25 Jan 2016, 141 (3), 902–909. 1.3 MB. https://doi.org/10.1039/c5an02326b
Brandt, SD; Kavanagh, PV. Addressing the challenges in forensic drug chemistry. Drug Test. Anal., 1 Mar 2017, 9 (3), 342-346. 120 kB. https://doi.org/10.1002/dta.2169
Burns, L; Roxburgh, A; Bruno, R; Van Buskirk, J. Monitoring drug markets in the Internet age and the evolution of drug monitoring systems in Australia. Drug Test. Anal., 1 Jul 2014, 6 (7-8), 840-845. 113 kB. https://doi.org/10.1002/dta.1613
Wenthur, CJ. Classics in Chemical Neuroscience: Methylphenidate. ACS Chem. Neurosci., 17 Aug 2016, 7 (8), 1030–1040. 531 kB. https://doi.org/10.1021/acschemneuro.6b00199 #9
Kraemer, M; Boehmer, A; Madea, B; Maas, A. Death cases involving certain new psychoactive substances: A review of the literature. Forensic Sci. Int., 1 May 2019, 298, 186–267. 6.7 MB. https://doi.org/10.1016/j.forsciint.2019.02.021 #Ethylphenidate
Bork, W; Dahlenburg, R; Gimbel, M; Jacobsen-Bauer, A; Zörntlein, S. Herleitung Von Grenzwerten Der „nicht Geringen Menge“ Im Sinne Des Btmg. Toxichem Krimtech, 1 Jan 2019, 86 (1), 5–91. 4.4 MB. #PP-007
Carlier, J; Giorgetti, R; Varì, MR; Pirani, F; Ricci, G; Busardò, FP. Use of cognitive enhancers: methylphenidate and analogs. Eur. Rev. Med. Pharmacol. Sci., 1 Jan 2019, 23 (1), 3–15. 676 kB. https://doi.org/10.26355/eurrev_201901_16741 #EPH
Hägele, JS; Basrak, M; Schmid, MG. Enantioselective separation of novel psychoactive substances using a Lux® AMP 3 μm column and HPLC-UV. J. Pharm. Biomed. Anal., 5 Feb 2020, 179, 112967. 3.6 MB. https://doi.org/10.1016/j.jpba.2019.112967 #I2 LC